Solid Bio’s higher gene therapy dose for Duchenne MD runs smack into a fresh set of safety issues -- shares tumble
Solid Biosciences has just ricocheted into a new setback.A few months after reporting dismal responses from a small cohort of patients receiving its gene therapy for Duchenne muscular dystrophy, the biotech had a chance to increase the dose to what it felt would be an ideal level — and immediately ran into a serious adverse event that had to be reported to the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
